EUVIMEDEUVIMED entdecken
Randomisierte kontrollierte StudieKlinische Studie (Phase III)Multizentrische StudieOpen Access · CC BY 4.0

Immune-mediated adverse events in the randomized phase 3 TOPAZ-1 study of durvalumab plus gemcitabine and cisplatin in advanced biliary tract cancer

Lorenzo Antonuzzo iD, Hidenori Takahashi, Joon Oh Park iD, Aumkhae Sookprasert, Roopinder Gillmore, Sheng-Shun Yang iD, Juan Cundom, Mila Petrova, Gina Vaccaro, Marielle Holmblad, Magdalena Żotkiewicz, Julie Wang und 2 weitere

The Oncologist · 04.07.2025 · 30 (7)

DOI: 10.1093/oncolo/oyaf148 ↗

Kurz gefasst

Randomisierte kontrollierte Studie in der Zeitschrift The Oncologist, online erschienen am 07.07.2025. Verfasst von Lorenzo Antonuzzo und 13 weiteren Autor:innen. Beteiligte Einrichtung: Clinical Oncology Unit, Careggi University Hospital, and Department of Experimental and Clinical Medicine, University of Florence, Largo Brambilla 3,…. Hauptthemen laut MEDLINE: Deoxycytidine, Biliary Tract Neoplasms, Antibodies, Monoclonal, Antineoplastic Combined Chemotherapy Protocols. Die Arbeit wurde bisher 6-mal zitiert (Crossref) und nennt 11 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: AstraZeneca.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Introduction

We assessed immune-mediated adverse events (imAEs) in the TOPAZ-1 (NCT03875235) study of durvalumab plus gemcitabine and cisplatin (GemCis) in advanced biliary tract cancer (aBTC).

Methods

Participants were randomized 1:1 to durvalumab (1500 mg) or placebo, plus GemCis (gemcitabine [1000 mg/m2] and cisplatin [25 mg/m2]) intravenously, followed by durvalumab (1500 mg) or placebo Q4W. We assessed imAE incidence, time to onset (TTO), and association with overall survival (OS).

Results

In durvalumab (n = 338) versus placebo (n = 342), imAEs were reported in 13.9% versus 4.7% of participants, with median TTO of 127.0 versus 86.5 days, respectively. OS HR for durvalumab versus placebo in participants with imAEs was 0.59 (95% CI, 0.30-1.23) and was 0.83 (95% CI, 0.70-1.00) in participants without imAEs.

Conclusions

Durvalumab demonstrated an OS benefit versus placebo in aBTC, irrespective of imAEs, which were mostly low grade and manageable. The results in these subgroups were consistent with the overall primary analysis.

Trial registration

ClinicalTrials.gov NCT03875235

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

DeoxycytidineBiliary Tract NeoplasmsAntibodies, MonoclonalAntineoplastic Combined Chemotherapy ProtocolsHumansGemcitabineCisplatinMaleFemaleMiddle AgedAgedAdult

Stichwörter der Autor:innen

Biliary tract neoplasmscholangiocarcinomagallbladder neoplasmsimmune checkpoint inhibitorimmunotherapy

Substanzen

DeoxycytidinedurvalumabGemcitabineCisplatinAntibodies, Monoclonal

Autor:innen und Institutionen

  • Clinical Oncology Unit, Careggi University Hospital, and Department of Experimental and Clinical Medicine, University of Florence, Largo Brambilla 3, 50134, Florence, Italy.
  • Department of Gastroenterological Surgery, Osaka International Cancer Institute, 3-1-69, Otemae, Chuo-Ku, Osaka, 541-8567, Japan.
  • Division of Hematology-Oncology, Department of Medicine, Samsung Medical Center, Sungkyunkwan University School of Medicine, 81 Irwon-ro, Gangnam-gu, Seoul 06351, South Korea.
  • Medical Oncology Unit, Department of Medicine, Faculty of Medicine, Khon Kaen University, 123 Mittraparp Road, Muang, Khon Kaen 40002, Thailand.
  • Department of Medical Oncology, Royal Free Hospital, Pond Street, London, NW3 2QG, UK.
  • Division of Gastroenterology and Hepatology, Department of Internal Medicine, Taichung Veterans General Hospital, 1650 Taiwan Boulevard, Section 4, Taichung, 40705, Taiwan.

ORCID-Profile: Lorenzo Antonuzzo, Joon Oh Park, Sheng-Shun Yang

Förderung

  • AstraZeneca

Zitieren

APA

Antonuzzo, L., Takahashi, H., Park, J. O., Sookprasert, A., Gillmore, R., Yang, S. S., Cundom, J., Petrova, M., Vaccaro, G., Holmblad, M., Żotkiewicz, M., Wang, J., Rokutanda, N., & Oh, D. Y. (2025). Immune-mediated adverse events in the randomized phase 3 TOPAZ-1 study of durvalumab plus gemcitabine and cisplatin in advanced biliary tract cancer. The Oncologist, 30(7). https://doi.org/10.1093/oncolo/oyaf148

Vancouver

Antonuzzo L, Takahashi H, Park JO, Sookprasert A, Gillmore R, Yang SS, et al. Immune-mediated adverse events in the randomized phase 3 TOPAZ-1 study of durvalumab plus gemcitabine and cisplatin in advanced biliary tract cancer. The Oncologist. 2025;30(7). doi:10.1093/oncolo/oyaf148

BibTeX
@article{Antonuzzo2025,
  author = {Antonuzzo, Lorenzo and Takahashi, Hidenori and Park, Joon Oh and Sookprasert, Aumkhae and Gillmore, Roopinder and Yang, Sheng-Shun and Cundom, Juan and Petrova, Mila and Vaccaro, Gina and Holmblad, Marielle and Żotkiewicz, Magdalena and Wang, Julie and Rokutanda, Nana and Oh, Do-Youn},
  title = {Immune-mediated adverse events in the randomized phase 3 TOPAZ-1 study of durvalumab plus gemcitabine and cisplatin in advanced biliary tract cancer},
  journal = {The Oncologist},
  year = {2025},
  volume = {30},
  number = {7},
  doi = {10.1093/oncolo/oyaf148}
}
Kostenlos starten →